Go online to PeerView.com/YMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) are the next frontier in the treatment of lung cancer, addressing unmet needs, expanding options, and providing new hope of improved outcomes for diverse populations of patients. Extensive efforts are ongoing to evaluate and bring new ADCs to clinical practice, including those targeting HER3 and TROP2. Initial studies have already yielded promising new data, and many other clinical trials are actively evaluating ADCs targeting HER3, TROP2, and others in different patient populations and treatment settings. This educational activity, based on a recent live symposium, provides an expert-led exploration of the fast-paced evolution of the role and impact of ADC-based approaches in lung cancer. Learners can achieve a better understanding of the structure and function of modern ADCs, the rationale for targeting HER3 and TROP2 with ADCs in lung cancer, and the rapidly accumulating evidence base supporting their use in practice. Going beyond the basics, the expert panel also shares in-depth perspectives on where the novel ADCs may fit within the complex lung cancer treatment arsenal, nuances of patient selection, how to best integrate them into treatment plans, and how to recognize and manage unique adverse events associated with different ADCs. Watch this activity to learn how to maximize the potential of these novel ADCs for the benefit of patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting HER3 and TROP2 with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and safety and efficacy profiles of ADCs targeting HER3 and TROP2 in NSCLC; Identify patients with NSCLC who are likely to be appropriate candidates for treatment with novel ADCs targeting HER3 and TROP2; and Implement best practices to effectively and safely integrate novel ADCs, including those targeting HER3 and TROP2, into treatment plans for appropriate patients with NSCLC